BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients.

Sebastiano ButiFrancesca TrentiniPierangela SepeMelanie ClapsLuca IsellaElena VerzoniGiuseppe Procopio

Published in: Tumori (2022)

Nivolumab may be considered as second-line therapy option after cabozantinib failure in selected metastatic collecting duct carcinoma patients.

Keyphrases